Matching articles for "Tecartus"

In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)

   
The Medical Letter on Drugs and Therapeutics • June 12, 2023;  (Issue 1678)
Brexucabtagene autoleucel (Tecartus – Kite) has been approved by the FDA for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It was previously approved...
Brexucabtagene autoleucel (Tecartus – Kite) has been approved by the FDA for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It was previously approved for treatment of relapsed or refractory mantle cell lymphoma. Tecartus is an individualized cellular product prepared from the patients own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. The CAR T-cell immunotherapy tisagenlecleucel (Kymriah) was approved in 2017 for treatment of relapsed or refractory B-cell precursor ALL in patients ≤25 years old.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e105-6 | Show Full IntroductionHide Full Introduction